The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Launched by ASAN MEDICAL CENTER · Dec 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective and safe a combination of medications—aspirin, clopidogrel, and cilostazol—can be for treating patients who have experienced an acute ischemic stroke due to large artery atherosclerosis. Ischemic stroke occurs when blood flow to the brain is blocked, and this trial aims to see if adding cilostazol to the standard treatment can help prevent early recurrence of stroke and improve recovery for patients with certain types of artery blockages.

To be eligible for this trial, participants need to be at least 20 years old and have had a recent stroke caused by significant narrowing of the arteries supplying blood to the brain. They must also be able to start the study medications within 72 hours of the stroke. Participants who join the trial can expect to receive close monitoring and care during their treatment. It's important to note that certain patients, such as those with large strokes or specific medical conditions, may not be able to participate. If you're interested or know someone who might be eligible, it could be helpful to discuss this trial with a healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age of 20 years or older
• • 2. Acute ischemic stroke due to large artery atherosclerosis (both including Intra and extracranial atherosclerosis) which may be defined by a ischemic lesion confirmed at diffusion-weighted image and a corresponding significant stenosis (more than 50% of diameter reduction) proximal to the ischemic lesion confirmed by MR or CT angiography.
• • 3. Able to start IMP within 72h from stroke onset
• • 4. Acquisition of written informed consent prior to study entry
• Exclusion Criteria:
• • 1. Large infarction unable to start antiplatelet treatment
• • 2. Combined with acute intracranial haemorrhage
• • 3. With initial haemorrhagic transformation
• • 4. Previous mRS higher than 2
• • 5. Indicated for anticoagulation
• • 6. Contraindication for aspirin, clopidogrel or cilostazol
• • 7. Requirement of long term NSAID
• • 8. Pre-planned for surgery
• • 9. Unable to withdraw consent
• • 10. Unavailable to participate based on judgement of the investigator
• • 11. Participants of reproductive potential (PORP)/ Participants of childbearing potential (POCBP) who do not agree to practice methods of birth control or remain fully abstinent from sexual activity with the potential for conception.